ArticleRadiation oncology (London, England)2025
Implementation of ultra-hypofractionated radiotherapy for breast cancer in the Netherlands in 2020-2023, using registry data and questionnaires.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study investigated the implementation of ultra-hypofractionated radiotherapy (i.e. 5 fractions) in DCIS and early-stage breast cancer, factors associated with its use, and variation across radiotherapy institutes.
methodsRegistry and questionnaire data were used. Registry data included data from the Netherlands Cancer Registry and the NABON Breast Cancer Audit-Radiotherapy (NBCA-R). Women eligible for 5 fractions were included. Trends and variation were visualised using trendlines and case-mix adjusted boxplots. Logistic regression was applied to investigate which factors were associated with the use of 5 fractions. In April 2024 a questionnaire was distributed among radiotherapy institutes to identify facilitators and barriers for implementation.
resultsThe current study included 16,115 women. In 2020, 18.5% of the eligible women received 5 fractions, compared to 60.8% in 2023. The lowest variation between radiotherapy institutes was found in 2023 (median: 60.4%, interquartile range: 53.3-70.6%). Age, tumour grade, multifocality, (y)pT, (y)pN, radiotherapy target volume, type of radiotherapy institute, and start year of radiation were associated with the chance of receiving 5 fractions. Sixteen out of the 19 radiotherapy institutes completed the questionnaire, showing variation in age and radiotherapy target volume for which the schedule was used. Most institutes mentioned no barriers for using 5 fractions. Questionnaire data confirmed the trendline finding that national consensus meetings were essential for largescale implementation.
conclusionsThe use of ultra-hypofractionated radiotherapy has increased during the past four years, with reduced variation across Dutch institutes. Registry and questionnaire data indicated that national consensus meetings were instrumental in driving implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.